Tiltan Pharma Ltd.
🇮🇱Israel
- Country
- 🇮🇱Israel
- Ownership
- Private
- Established
- 2006-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://tiltanpharma.com
Investigator's Initiated Phase II Study for Pancreatic Cancer Patients
Phase 2
- Conditions
- Pancreatic Cancer
- Interventions
- Drug: TL-118
- First Posted Date
- 2012-08-07
- Last Posted Date
- 2013-12-05
- Lead Sponsor
- Tiltan Pharma Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT01659502
- Locations
- 🇮🇱
Hadassah Medical Center, Jerusalem, Israel
A Clinical Trial of Anti-Angiogenic Drug Combination Tl-118 for Pancreatic Cancer Patients Who Are Starting Gemcitabine Treatment
- First Posted Date
- 2012-01-13
- Last Posted Date
- 2016-02-05
- Lead Sponsor
- Tiltan Pharma Ltd.
- Target Recruit Count
- 99
- Registration Number
- NCT01509911
- Locations
- 🇮🇱
Soroka Medical Center, Be'er Sheva, Israel
🇮🇱HaEmek Medical Center, Afula, Israel
🇮🇱Sourasky Medical Center, Tel-Aviv, Israel
Phase IIB Clinical Trial of Hamsa-1â„¢ in Metastatic Castration Resistant Prostate Cancer (CRPC)
Phase 2
- Conditions
- Metastatic Castration Resistant Prostate Cancer (CRPC)
- Interventions
- Drug: Hamsa-1â„¢ TL-118
- First Posted Date
- 2008-05-28
- Last Posted Date
- 2013-12-05
- Lead Sponsor
- Tiltan Pharma Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT00684970
- Locations
- 🇮🇱
Rambam Medical Center, Haifa, Israel
🇮🇱Sourasky Medical Center, Tel-Aviv, Israel
🇮🇱Bnei Tzion Medical Center, Haifa, Israel
© Copyright 2025. All Rights Reserved by MedPath